AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts
AbbVie Inc. (NYSE: ABBV) heads into the Monday, December 22, 2025 U.S. market open with a familiar bull case—Skyrizi and Rinvoq continuing to replace lost Humira revenue—and a less familiar overhang: Washington’s accelerating push to reframe U.S. drug pricing through “most‑favored‑nation” style commitments and new direct-to-consumer programs. Below is what investors and traders should keep on their radar before the opening bell, using the most recent available company updates, analyst forecasts, and late‑breaking policy developments. 1) Where AbbVie stock stands heading into Monday AbbVie last closed at $226.82 (Friday, Dec. 19), up about 1.8% on the day. StockAnalysis+1 One detail